HeyJaredThe Biohub
Go inside biotech with the people building it. The BioHub brings you candid conversations with biotech founders, executives, scientists and investors shaping the future of medicine.
- Indexed videos, last 90 days
- 21
- Latest publication
- Sep 28, 2026
- Audience
- ~381 subscribers
- Earliest in this view
- Jul 6, 2026
Latest videos
How a Shelved Drug Became a $7.3 Billion Biotech Exit | Edward van Wezel (opens the original)
Read excerpt
A drug programme had been shelved. A team saw potential in it, licensed it from Merck and built Acerta Pharma around it. Edward van Wezel, Managing Partner and Co-Founder of BioGeneration Ventures, explains how the programme developed into a $7.3 billion deal with AstraZeneca—and why the right scientific and commercial team mattered. In this episode of The BioHub, Edward joins Max Brennan to discuss what BGV looks for in an early-stage biotech, how funding and exit expectations have changed, and
$77M Bet on Two-Target Cancer Drugs | InduPro CEO Prakash Raman (opens the original)
Read excerpt
$77 million raised, a first patient dosed—and a biotech thesis built around one question: what if the right cancer target isn’t one protein, but a pair? Recorded on the day InduPro announced its Series B financing and the first patient dosed in the Phase 1 study of IDP-001, this episode features InduPro CEO Prakash Raman. IDP-001 is an investigational bispecific antibody-drug conjugate designed to target EGFR alongside TAPA-E1, a tumour-associated proximity antigen identified through InduPro’s p
Can One Oral Drug Target Crohn’s and Ulcerative Colitis? | Palisade Bio (opens the original)
Read excerpt
Can one oral drug target both Crohn’s disease and ulcerative colitis? Palisade Bio CEO JD Finley and President & Chief Medical Officer Dr Mitchell Jones join The BioHub to explore PALI-2108—an investigational oral PDE4 inhibitor prodrug being developed for inflammatory bowel disease. They discuss: • How Palisade Bio rebuilt its pipeline around PALI-2108 • How targeted bioactivation in the gut is designed to reduce systemic side effects • The early Phase 1 findings in ulcerative colitis and fibro
Can Gene Therapy Preserve Sight? Ikarovec’s New Approach to Geographic Atrophy | Thomas Ciulla (opens the original)
Read excerpt
Can gene therapy move retinal disease beyond repeated injections and slowing progression — towards actually preserving meaningful vision? Thomas Ciulla, President & CEO of Ikarovec, joins The BioHub to discuss the evolution of ophthalmology, geographic atrophy and the science behind Ikarovec's dual-pathway gene therapy approach. Thomas brings more than 25 years of experience across ophthalmology, clinical research and biotech, including involvement in the development of four FDA-approved therapi
What VCs Are Really Thinking During Your Biotech Pitch #investing #biotech (opens the original)
Read excerpt
What is a biotech investor actually trying to understand during a 30-minute pitch? Former life-sciences VC and Artiva CEO Fred Aslan explains why understanding competition, risk and the investor’s unanswered questions matters more than delivering the same rehearsed presentation. Watch the full conversation here: https://youtu.be/I9eCndzNTAI #Shorts #Biotech #VentureCapital Fred Aslan Artiva Biotherapeutics biotech venture capital biotech fundraising biotech investors NK cell therapy AlloNK cell
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
~381 subscribers
Measured Sep 19, 2026
Source's subscribers, not the number who saw an individual piece.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.